Heart failure & cardiomyopathiesMechanistic study
Sodium–Glucose Cotransporter 2 Inhibitors Influence Skeletal Muscle Pathology in Patients with Heart Failure and Reduced Ejection Fraction
- Mechanistic study
- cross-sectional comparison
- mouse experiments
Authors' conclusion
Treatment with SGLT2i influenced skeletal muscle pathology in patients with HFrEF and was associated with anti-atrophic, anti-inflammatory, and pro-metabolic effects.
Study context
- Population
- Male patients with heart failure and reduced ejection fraction (HFrEF) (NYHA class I–III)plus mice n = 16
- Participants
- 28 patients
- Comparison
- SGLT2i vs no SGLT2i
Main finding
As reported in the abstract
Skeletal muscle pathology (myofiber atrophy, tryptophan metabolism, inflammation)
- Myofiber atrophy ~20% less with SGLT2i
- p = 0.07
- Muscle kynurenic acid 24% higher and kynurenine 32% lower with SGLT2i
- p < 0.001
- Serum pro-inflammatory cytokines lower by 26-64% with SGLT2i
- p < 0.05
- Downstream muscle IL-6-JAK/STAT3 signalling lower with SGLT2i
- p = 008 and 0.09
- Serum IL-6 and muscle kynurenine correlated (R = 0.65)
- p < 0.05
Original publication
Sodium–Glucose Cotransporter 2 Inhibitors Influence Skeletal Muscle Pathology in Patients with Heart Failure and Reduced Ejection Fraction. Eur J Heart Fail. Published 11 March 2024. doi:10.1002/ejhf.3192
Summarised from the published abstract; every number is checked against it